Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.

Published online

Journal Article

BACKGROUND: Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience with response prediction based on PD-L1 expression suggests that other factors influence sensitivity to ICIs in non-small cell lung cancer (NSCLC) patients. METHODS: Tumor specimens from 120 NSCLC patients from 10 institutions were evaluated for PD-L1 expression by immunohistochemistry, and global proliferative profile by targeted RNA-seq. RESULTS: Cell proliferation, derived from the mean expression of 10 proliferation-associated genes (namely BUB1, CCNB2, CDK1, CDKN3, FOXM1, KIAA0101, MAD2L1, MELK, MKI67, and TOP2A), was identified as a marker of response to ICIs in NSCLC. Poorly, moderately, and highly proliferative tumors were somewhat equally represented in NSCLC, with tumors with the highest PD-L1 expression being more frequently moderately proliferative as compared to lesser levels of PD-L1 expression. Proliferation status had an impact on survival in patients with both PD-L1 positive and negative tumors. There was a significant survival advantage for moderately proliferative tumors compared to their combined highly/poorly counterparts (p = 0.021). Moderately proliferative PD-L1 positive tumors had a median survival of 14.6 months that was almost twice that of PD-L1 negative highly/poorly proliferative at 7.6 months (p = 0.028). Median survival in moderately proliferative PD-L1 negative tumors at 12.6 months was comparable to that of highly/poorly proliferative PD-L1 positive tumors at 11.5 months, but in both instances less than that of moderately proliferative PD-L1 positive tumors. Similar to survival, proliferation status has impact on disease control (DC) in patients with both PD-L1 positive and negative tumors. Patients with moderately versus those with poorly or highly proliferative tumors have a superior DC rate when combined with any classification schema used to score PD-L1 as a positive result (i.e., TPS ≥ 50% or ≥ 1%), and best displayed by a DC rate for moderately proliferative tumors of no less than 40% for any classification of PD-L1 as a negative result. While there is an over representation of moderately proliferative tumors as PD-L1 expression increases this does not account for the improved survival or higher disease control rates seen in PD-L1 negative tumors. CONCLUSIONS: Cell proliferation is potentially a new biomarker of response to ICIs in NSCLC and is applicable to PD-L1 negative tumors.

Full Text

Duke Authors

Cited Authors

  • Pabla, S; Conroy, JM; Nesline, MK; Glenn, ST; Papanicolau-Sengos, A; Burgher, B; Hagen, J; Giamo, V; Andreas, J; Lenzo, FL; Yirong, W; Dy, GK; Yau, E; Early, A; Chen, H; Bshara, W; Madden, KG; Shirai, K; Dragnev, K; Tafe, LJ; Marin, D; Zhu, J; Clarke, J; Labriola, M; McCall, S; Zhang, T; Zibelman, M; Ghatalia, P; Araujo-Fernandez, I; Singavi, A; George, B; MacKinnon, AC; Thompson, J; Singh, R; Jacob, R; Dressler, L; Steciuk, M; Binns, O; Kasuganti, D; Shah, N; Ernstoff, M; Odunsi, K; Kurzrock, R; Gardner, M; Galluzzi, L; Morrison, C

Published Date

  • February 1, 2019

Published In

Volume / Issue

  • 7 / 1

Start / End Page

  • 27 -

PubMed ID

  • 30709424

Pubmed Central ID

  • 30709424

Electronic International Standard Serial Number (EISSN)

  • 2051-1426

Digital Object Identifier (DOI)

  • 10.1186/s40425-019-0506-3

Language

  • eng

Conference Location

  • England